I wrote here about the Myriad Genetics decision last week.
Today, I'll review what everyone else is saying.
Stephen Jenei, at Patent Baristas, confined himself to a paraphrase of the decision.
Investment bankers are mixed. In the wake of the decision, some upgraded their view of Myriad's prospects, which seems odd. Perhaps it's just the fact that the company has gotten the bad news behind it. Or perhaps it's because in some ways the news could have been worse.
Patent Hawk thinks the circuit court decision that the Supreme Court overturned was simply "incompetent." That characterization belies his pen name a bit. The circuit court's own hawkishness does have defenders.
At any rate, the phrase "patent hawk" inspired a visual for this blog entry. See above.
Dennis Crouch at PatentlyO, had "twenty thoughts on the importance of Myriad." One of these thoughts is a quote from John Duffy to the effect that the decision is "a full victory for patent lawyers, who will have lots of business opining on, and litigating, the complexities of this decision."
Eric Guttag at IPWatchdog has another take: because of this decision, "there should be less impetus from Congress to enact legislation like the inane bills authored by Congressman Xavier Becerra ... that would truly plunge us into an 'anti-gene patenting hell.'"
Here's something Guttag wrote about the Becerra bill three years ago.
Finally, here is some triumphalism from the ACLU.
Comments
Post a Comment